Published in Cancer Res on November 01, 1988
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res (2009) 2.04
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS One (2014) 1.99
Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res (2012) 1.87
Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene (2010) 1.73
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol (2012) 1.71
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther (2011) 1.70
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res (2011) 1.28
Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer (2012) 1.27
DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia (2011) 1.15
Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation. Cancer Res (2010) 1.09
Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia (2008) 1.08
Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis. Cancer Res (2010) 1.07
Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci (2011) 1.05
Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa"). Br J Cancer (2002) 1.05
Characterization of three new serous epithelial ovarian cancer cell lines. BMC Cancer (2008) 1.02
Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas. Br J Cancer (2001) 1.01
Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer. PLoS One (2012) 1.00
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol Oncol (2013) 1.00
Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. Br J Cancer (1990) 0.99
Cytotoxic response of ovarian cancer cell lines to IFN-gamma is associated with sustained induction of IRF-1 and p21 mRNA. Br J Cancer (1999) 0.96
Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo. Int J Cancer (2012) 0.95
Increased expression of the RIalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer. Br J Cancer (1999) 0.94
Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors. Am J Hum Genet (1994) 0.94
The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer. Cancer Discov (2012) 0.94
Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer. BMC Cancer (2012) 0.92
Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment. Oncogene (2013) 0.89
Differential expressions of adhesive molecules and proteases define mechanisms of ovarian tumor cell matrix penetration/invasion. PLoS One (2011) 0.89
Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma. Br J Cancer (2005) 0.89
Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells. Cancer Med (2015) 0.89
Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. Br J Cancer (2001) 0.88
ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest (2013) 0.88
Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer. Br J Cancer (2012) 0.88
Transforming growth factor-beta mRNA expression and growth control of human ovarian carcinoma cells. Br J Cancer (1992) 0.87
Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells. BMC Cancer (2015) 0.86
Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity. J Ovarian Res (2014) 0.84
Methylation status of oestrogen receptor-alpha gene promoter sequences in human ovarian epithelial cell lines. Br J Cancer (2002) 0.84
E3 ubiquitin ligase HOIP attenuates apoptotic cell death induced by cisplatin. Cancer Res (2014) 0.84
Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer. Cell Death Differ (2016) 0.84
Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20. Br J Cancer (1997) 0.84
Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism. Cancer Lett (2016) 0.83
Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell lines. Br J Cancer (1999) 0.83
The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity. Mol Cancer Ther (2014) 0.83
Inflammation-associated gene expression is altered between normal human ovarian surface epithelial cells and cell lines derived from ovarian adenocarcinomas. Br J Cancer (2005) 0.82
Analysis of diazofluorene DNA binding and damaging activity: DNA cleavage by a synthetic monomeric diazofluorene. Angew Chem Int Ed Engl (2014) 0.82
Modeling platinum sensitive and resistant high-grade serous ovarian cancer: development and applications of experimental systems. Front Oncol (2014) 0.81
Eribulin mesylate targets human telomerase reverse transcriptase in ovarian cancer cells. PLoS One (2014) 0.81
Increased gastrin-releasing peptide (GRP) receptor expression in tumour cells confers sensitivity to [Arg6,D-Trp7,9,NmePhe8]-substance P (6-11)-induced growth inhibition. Br J Cancer (2003) 0.80
Inhibition of transforming growth factor alpha (TGF-alpha)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868. Br J Cancer (1999) 0.80
RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian Cancer. Mol Cancer Res (2015) 0.80
ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer (2016) 0.80
The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer. Oncotarget (2016) 0.78
Decreased expression of the Id3 gene at 1p36.1 in ovarian adenocarcinomas. Br J Cancer (2001) 0.78
The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer. Oncotarget (2016) 0.78
Up-regulation of the interferon-related genes in BRCA2 knockout epithelial cells. J Pathol (2014) 0.78
The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma. Oncotarget (2015) 0.78
Transcriptional regulation of hTREX84 in human cancer cells. PLoS One (2012) 0.78
Limitations of three-dimensional power Doppler angiography in preoperative evaluation of ovarian tumors. J Ovarian Res (2015) 0.78
Preventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer Therapy. Front Oncol (2015) 0.78
NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies. Oxid Med Cell Longev (2015) 0.77
Cytokeratin 5-Positive Cells Represent a Therapy Resistant subpopulation in Epithelial Ovarian Cancer. Int J Gynecol Cancer (2015) 0.77
TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial-mesenchymal transition. Cell Death Dis (2016) 0.77
Characterisation of seven human ovarian tumour cell lines. Br J Cancer (1996) 0.77
Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. Onco Targets Ther (2017) 0.77
Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer. Sci Rep (2017) 0.76
Establishment of a New Ovarian Cancer Cell Line CA5171. Reprod Sci (2014) 0.76
Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease. Genes Cancer (2015) 0.76
Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer. Clin Cancer Res (2016) 0.76
Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients. J Inorg Biochem (2015) 0.75
Identification of therapeutic targets applicable to clinical strategies in ovarian cancer. BMC Cancer (2016) 0.75
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib. BMC Cancer (2016) 0.75
Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecol Oncol (2016) 0.75
Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens. Clin Cancer Res (2017) 0.75
Susceptibility of group D streptococcus (enterococcus) to 21 antibiotics in vitro, with special reference to species differences. Am J Med Sci (1969) 10.08
Neonatal examination and screening trial (NEST): a randomised, controlled, switchback trial of alternative policies for low risk infants. BMJ (1999) 3.63
Detection of avian and mammalian oncogenic RNA viruses (oncornaviruses) by immunofluorescence. Cancer Res (1972) 3.23
A study of the reliability and comparative validity of the cardia dietary history. Ethn Dis (1994) 3.05
A complex of platelet glycoproteins Ic and IIa identified by a rat monoclonal antibody. J Biol Chem (1987) 2.94
WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A (2001) 2.79
A prognostic model for ovarian cancer. Br J Cancer (2001) 2.77
Iron-deficiency anaemia: its effect on transfer factor for the lung (diffusiong capacity) and ventilation and cardiac frequency during sub-maximal exercise. Clin Sci (1972) 2.41
Malignant melanoma in Scotland 1979-1983. Lancet (1985) 2.30
Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol (1999) 2.13
Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer (1984) 2.12
Children, stress, and hospitalization: a field experiment. J Health Soc Behav (1968) 2.11
Epstein-Barr virus-associated complement-fixing and nuclear antigens in Burkitt lymphoma biopsies. Int J Cancer (1974) 2.10
THE EFFECT OF UREA, URETHANE AND OTHER CARBAMATES ON BACTERIAL GROWTH. Science (1945) 2.02
Primary prevention of hypertension by nutritional-hygienic means. Final report of a randomized, controlled trial. JAMA (1989) 2.02
Homograft replacement of the aortic valve. Immediate results and follow-up. Lancet (1968) 1.85
Variations among sublines of inbred AKR mice. Nat New Biol (1973) 1.78
Cerebral palsy and severe educational subnormality in low-birthweight children: a comparison of births in 1951-53 and 1970-73. Lancet (1982) 1.77
Light chain isotype-associated suppression of normal plasma cell numbers in patients with multiple myeloma: Medical Research Council's Working Party for Leukaemia in Adults and the Oxford Lymphoma Group. Int J Cancer (1979) 1.75
H-2-linked control of in vitro gamma interferon production in response to a 32-kilodalton antigen (P32) of Mycobacterium bovis bacillus Calmette-Guérin. Infect Immun (1988) 1.73
Types of urethral catheter for reducing symptomatic urinary tract infections in hospitalised adults requiring short-term catheterisation: multicentre randomised controlled trial and economic evaluation of antimicrobial- and antiseptic-impregnated urethral catheters (the CATHETER trial). Health Technol Assess (2012) 1.66
Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol (1990) 1.66
Plasma-catecholamines after cardiac infarction. Lancet (1969) 1.64
The human tumour xenograft--a valid model in experimental chemotherapy? Br J Surg (1980) 1.63
Sperm motility in the presence of boundaries. Bull Math Biol (1995) 1.61
Development of mouse mammary gland: identification of stages in differentiation of luminal and myoepithelial cells using monoclonal antibodies and polyvalent antiserum against keratin. J Histochem Cytochem (1986) 1.61
Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol (2000) 1.60
Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol (1994) 1.58
Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg (1994) 1.57
Interferon treatment of NZB mice: accelerated progression of autoimmune disease. Infect Immun (1978) 1.53
Acquisition of proviral DNA of mouse mammary tumor virus in thymic leukemia cells from GR mice. J Virol (1982) 1.53
In vitro infection of lymphoid cells by thymotropic radiation leukemia virus grown in vitro. Proc Natl Acad Sci U S A (1975) 1.52
Interaction between viral and genetic factors in murine mammary cancer. Adv Cancer Res (1978) 1.51
The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer (1996) 1.51
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol (2008) 1.50
Effects of variations in the environment, length of journey and type of trailer on the mortality and morbidity of pigs being transported to slaughter. Vet Rec (2009) 1.50
Small-cell lung cancer after retinoblastoma. Lancet (1989) 1.48
Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int J Cancer (1987) 1.47
Chromosomal aberration and sister-chromatid exchange frequencies in peripheral blood lymphocytes of a large human population sample. II. Extension of age range. Mutat Res (1989) 1.46
Expression of neural cell adhesion molecule-related sialoglycoprotein in small cell lung cancer and neuroblastoma cell lines H69 and CHP-212. Cancer Res (1990) 1.46
Immunoperoxidase staining of surface and intracellular immunoglobulin in human neoplastic lymphoid cells. J Clin Pathol (1980) 1.45
The natural history of low grade non-Hodgkin's lymphoma and the impact of a no initial treatment policy on survival. Q J Med (1991) 1.45
p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res (1993) 1.45
A comparison of two methods to ascertain dietary intake: the CARDIA Study. J Clin Epidemiol (1994) 1.44
The therapeutic response of bronchial carcinoma xenografts: a direct patient-xenograft comparison. Br J Cancer Suppl (1980) 1.44
A new hereditary cataract mouse with lens rupture. Lab Anim (1997) 1.44
Antigens on human plasma cells identified by monoclonal antibodies. J Immunol (1983) 1.41
Role of adenosine deaminase in lymphocyte proliferation. Clin Exp Immunol (1976) 1.41
Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996. Tumour Biol (1998) 1.40
A human tumour model. Lancet (1986) 1.39
An improved murine leukemia virus immunofluorescence assay. Virology (1974) 1.39
A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. Cancer Res (2000) 1.39
Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol (1992) 1.38
Normal G2 chromosomal radiosensitivity and cell survival in the cancer family syndrome. Cancer Res (1988) 1.37
Localization of a gene controlling the expression of the human transferrin receptor to the region q12 leads to qter of chromosome 3. Cytogenet Cell Genet (1983) 1.34
(Alpha)3(beta)1 integrin regulates epithelial cytoskeletal organization. J Cell Sci (1999) 1.33
Tamoxifen as primary treatment of breast cancer in elderly or frail patients: a practical management. Br Med J (Clin Res Ed) (1985) 1.29
Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia. Lancet (1980) 1.29
Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation. Arch Fam Med (1998) 1.28
Aromatase inhibitors and arthralgia. J Clin Oncol (2001) 1.27
The impact of chemotherapy on small cell carcinoma of the bronchus. Q J Med (1986) 1.26
Associations of body fat and its distribution with dietary intake, physical activity, alcohol, and smoking in blacks and whites. Am J Clin Nutr (1992) 1.23
Ablation of AMP-activated protein kinase alpha1 and alpha2 from mouse pancreatic beta cells and RIP2.Cre neurons suppresses insulin release in vivo. Diabetologia (2010) 1.22
Information giving in oncology: a preliminary study of tape-recorder use. Br J Clin Psychol (1992) 1.22
Mouse lymphotoxin and tumor necrosis factor: structural analysis of the cloned genes, physical linkage, and chromosomal position. J Immunol (1987) 1.21
Association of prolapse of posterior cusp of mitral valve and atrial septal defect. Br Heart J (1971) 1.20
Chemotherapy for ovarian cancer--a consensus statement on standard practice. Br J Cancer (1998) 1.19
Allele losses on chromosome 17 in human epithelial ovarian carcinoma. Oncogene (1990) 1.19
Adenosine deaminase activity in leukaemia. Br J Cancer (1975) 1.19
Primary systemic therapy for operable breast cancer. Br J Cancer (1991) 1.19
DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol (1993) 1.19
Distribution of monoclonal antibody-defined monosialoganglioside in normal and cancerous human tissues: an immunoperoxidase study. Hybridoma (1983) 1.18
Assessing the state of health research in the Eastern Mediterranean Region. J R Soc Med (2013) 1.17
Impaired maturation of mouse mammary tumor virus precursor polypeptides in lymphoid leukemia cells, producing intracytoplasmic A particles and no extracellular B-type virions. J Virol (1979) 1.17
Practolol in treatment of supraventricular cardiac dysrhythmias. Br Med J (1970) 1.16
Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe? Ann Oncol (2013) 1.16
Systemic hypertension after homograft aortic valvar replacement. A cause of late homograft failure. Lancet (1973) 1.16
Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol (1996) 1.16
Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int J Cancer (2000) 1.15
Mitral valve replacement with mechanical prostheses in children: improved operative risk and survival. Eur J Cardiothorac Surg (2001) 1.13
Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clin Pharmacol Ther (1985) 1.12
Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur J Cancer (1996) 1.11
Septicemia caused by Vibrio fetus. Arch Intern Med (1970) 1.10
Detection of antigens of the mouse mammary tumor (MTV) and murine leukemia virus (MuLV) in cells of cultures derived from mammary tumors of mice of several strains. Virology (1971) 1.10
Expression of the heat shock protein HSP27 in human ovarian cancer. Clin Cancer Res (1995) 1.10
Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer. Cancer Res (2001) 1.09
Immunologic, virologic, and genetic aspects of mammary tumor virus-induced cell-surface antigens: presence of these antigens and the Thy 1.2 antigen on murine mammary gland and tumor cells. J Natl Cancer Inst (1975) 1.08
Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer. Cancer Chemother Pharmacol (1984) 1.07
Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy. Br J Cancer (1997) 1.07
Diet, body size, and plasma lipids-lipoproteins in young adults: differences by race and sex. The Coronary Artery Risk Development in Young Adults (CARDIA) study. Am J Epidemiol (1991) 1.07
Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br J Cancer (1995) 1.07
Immunofluorescence and anti-complement immunofluorescence absorption tests for quantitation of Epstein-Barr virus-associated antigens. Int J Cancer (1975) 1.06